The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.
about
Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaShould involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.Epratuzumab in the therapy of oncological and immunological diseases.Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal origin.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal.The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.Subcellular S-factors for low-energy electrons: a comparison of Monte Carlo simulations and continuous-slowing-down calculations.Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia.Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Theoretical study of the influence of a heterogeneous activity distribution on intratumoral absorbed dose distribution.
P2860
Q24633710-3D776349-EF79-4E38-AE17-8A4127C8F049Q34541079-0C929ED3-708E-45D6-92E6-F686B5C426F7Q36082355-3F2514F8-4EF5-4DA2-A3C6-57C09FE2CCF0Q36569755-AB37D408-E6D7-4F80-A79C-9890AB0335CFQ36636619-9A0C17AB-0A2F-4729-B533-A26A36A90901Q37226204-72075376-C1C5-46FE-895B-EC1AFD2EC4C0Q37854714-C83B1C9D-F7A3-4A4B-A405-CF2CB2E52307Q38716531-7787AF9E-AF52-4FAA-B1CA-28CE85012887Q40426685-91365F2A-1D85-45F1-BF5E-0E14A067DC8AQ40563800-0AB8B193-FABB-46DD-81CF-E1D4E2BDE820Q47194411-7D7E6962-E9AE-4F28-9C29-37C79AD3A0BCQ47435794-0A607E3D-CCF4-4728-806D-AB96BF5646F8Q50962872-1A513DD0-25F4-4303-A479-D672E5E420A4Q51538938-E907BA1A-18AA-482C-AB0E-DD605405223C
P2860
The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@ast
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@en
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@nl
type
label
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@ast
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@en
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@nl
prefLabel
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@ast
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@en
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@nl
P1476
The role of radiolabeled antib ...... of age of radioimmunotherapy.
@en
P2093
Goldenberg DM
P304
P356
10.1016/S1040-8428(01)00108-1
P577
2001-07-01T00:00:00Z